Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections

Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical microbiology reviews 2023-06, Vol.36 (2), p.e0005922-e0005922
Main Authors: Cairns, Kelly A, Udy, Andrew A, Peel, Trisha N, Abbott, Iain J, Dooley, Michael J, Peleg, Anton Y
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - therapeutic use
Bacteremia - drug therapy
Clinical Microbiology
Gram-Positive Bacterial Infections - drug therapy
Humans
Linezolid - therapeutic use
Review
Sepsis
Vancomycin - pharmacology
Vancomycin - therapeutic use
Vancomycin-Resistant Enterococci
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3
cites cdi_FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3
container_end_page e0005922
container_issue 2
container_start_page e0005922
container_title Clinical microbiology reviews
container_volume 36
creator Cairns, Kelly A
Udy, Andrew A
Peel, Trisha N
Abbott, Iain J
Dooley, Michael J
Peleg, Anton Y
description Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.
doi_str_mv 10.1128/cmr.00059-22
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10283489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2802423070</sourcerecordid><originalsourceid>FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhi0EgmXbG-cqRyoROv5I4pwqQLSstFKlatWrNZk4EJTYW9tB4t83sFvUHjjNYR69o3lexs44XHIu9BcawyUAFHUuxAFbcKh1XpZcH7IF6FrmuuDihJ3G-AjAlZL6mJ3ICspKQblgq82DDbi1U-opZp0P2S905Mdn6l3-08Y-JnQpu3XJBk-eCIfsevC-jSlYHLOV6yyl3rv4gR11OET7cT-XbPPtdnNzl69_fF_dXK1zVLxOeatrglZAR6rGBgquG44l57zAWpWVthU1WmHXckmyU1I2XaULqjQWZVOQXLKvu9jt1Iy2JetSwMFsQz9ieDYee_P_xvUP5t4_GQ5CSzUbWbLzfULwvycbkxn7SHYY0Fk_RSM0CCUkVDCjFzuUgo8x2O7tDgfzYt_M9s2rfSPEjH_e4RhHYR79FNxs4j32079_vAX_rUb-AfW5jz0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2802423070</pqid></control><display><type>article</type><title>Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>Cairns, Kelly A ; Udy, Andrew A ; Peel, Trisha N ; Abbott, Iain J ; Dooley, Michael J ; Peleg, Anton Y</creator><creatorcontrib>Cairns, Kelly A ; Udy, Andrew A ; Peel, Trisha N ; Abbott, Iain J ; Dooley, Michael J ; Peleg, Anton Y</creatorcontrib><description>Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.</description><identifier>ISSN: 0893-8512</identifier><identifier>EISSN: 1098-6618</identifier><identifier>DOI: 10.1128/cmr.00059-22</identifier><identifier>PMID: 37067406</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - therapeutic use ; Bacteremia - drug therapy ; Clinical Microbiology ; Gram-Positive Bacterial Infections - drug therapy ; Humans ; Linezolid - therapeutic use ; Review ; Sepsis ; Vancomycin - pharmacology ; Vancomycin - therapeutic use ; Vancomycin-Resistant Enterococci</subject><ispartof>Clinical microbiology reviews, 2023-06, Vol.36 (2), p.e0005922-e0005922</ispartof><rights>Copyright © 2023 American Society for Microbiology.</rights><rights>Copyright © 2023 American Society for Microbiology. 2023 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3</citedby><cites>FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3</cites><orcidid>0000-0003-2370-2438 ; 0000-0002-6284-2022 ; 0000-0002-9969-3972 ; 0000-0001-6590-6127 ; 0000-0002-2296-2126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/cmr.00059-22$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/cmr.00059-22$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,315,730,783,787,888,3195,27936,27937,52763,52764,52765,53804,53806</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37067406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cairns, Kelly A</creatorcontrib><creatorcontrib>Udy, Andrew A</creatorcontrib><creatorcontrib>Peel, Trisha N</creatorcontrib><creatorcontrib>Abbott, Iain J</creatorcontrib><creatorcontrib>Dooley, Michael J</creatorcontrib><creatorcontrib>Peleg, Anton Y</creatorcontrib><title>Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections</title><title>Clinical microbiology reviews</title><addtitle>Clin Microbiol Reviews</addtitle><addtitle>Clin Microbiol Rev</addtitle><description>Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Bacteremia - drug therapy</subject><subject>Clinical Microbiology</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Humans</subject><subject>Linezolid - therapeutic use</subject><subject>Review</subject><subject>Sepsis</subject><subject>Vancomycin - pharmacology</subject><subject>Vancomycin - therapeutic use</subject><subject>Vancomycin-Resistant Enterococci</subject><issn>0893-8512</issn><issn>1098-6618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kU1P3DAQhi0EgmXbG-cqRyoROv5I4pwqQLSstFKlatWrNZk4EJTYW9tB4t83sFvUHjjNYR69o3lexs44XHIu9BcawyUAFHUuxAFbcKh1XpZcH7IF6FrmuuDihJ3G-AjAlZL6mJ3ICspKQblgq82DDbi1U-opZp0P2S905Mdn6l3-08Y-JnQpu3XJBk-eCIfsevC-jSlYHLOV6yyl3rv4gR11OET7cT-XbPPtdnNzl69_fF_dXK1zVLxOeatrglZAR6rGBgquG44l57zAWpWVthU1WmHXckmyU1I2XaULqjQWZVOQXLKvu9jt1Iy2JetSwMFsQz9ieDYee_P_xvUP5t4_GQ5CSzUbWbLzfULwvycbkxn7SHYY0Fk_RSM0CCUkVDCjFzuUgo8x2O7tDgfzYt_M9s2rfSPEjH_e4RhHYR79FNxs4j32079_vAX_rUb-AfW5jz0</recordid><startdate>20230621</startdate><enddate>20230621</enddate><creator>Cairns, Kelly A</creator><creator>Udy, Andrew A</creator><creator>Peel, Trisha N</creator><creator>Abbott, Iain J</creator><creator>Dooley, Michael J</creator><creator>Peleg, Anton Y</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2370-2438</orcidid><orcidid>https://orcid.org/0000-0002-6284-2022</orcidid><orcidid>https://orcid.org/0000-0002-9969-3972</orcidid><orcidid>https://orcid.org/0000-0001-6590-6127</orcidid><orcidid>https://orcid.org/0000-0002-2296-2126</orcidid></search><sort><creationdate>20230621</creationdate><title>Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections</title><author>Cairns, Kelly A ; Udy, Andrew A ; Peel, Trisha N ; Abbott, Iain J ; Dooley, Michael J ; Peleg, Anton Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Bacteremia - drug therapy</topic><topic>Clinical Microbiology</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Humans</topic><topic>Linezolid - therapeutic use</topic><topic>Review</topic><topic>Sepsis</topic><topic>Vancomycin - pharmacology</topic><topic>Vancomycin - therapeutic use</topic><topic>Vancomycin-Resistant Enterococci</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cairns, Kelly A</creatorcontrib><creatorcontrib>Udy, Andrew A</creatorcontrib><creatorcontrib>Peel, Trisha N</creatorcontrib><creatorcontrib>Abbott, Iain J</creatorcontrib><creatorcontrib>Dooley, Michael J</creatorcontrib><creatorcontrib>Peleg, Anton Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical microbiology reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cairns, Kelly A</au><au>Udy, Andrew A</au><au>Peel, Trisha N</au><au>Abbott, Iain J</au><au>Dooley, Michael J</au><au>Peleg, Anton Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections</atitle><jtitle>Clinical microbiology reviews</jtitle><stitle>Clin Microbiol Reviews</stitle><addtitle>Clin Microbiol Rev</addtitle><date>2023-06-21</date><risdate>2023</risdate><volume>36</volume><issue>2</issue><spage>e0005922</spage><epage>e0005922</epage><pages>e0005922-e0005922</pages><issn>0893-8512</issn><eissn>1098-6618</eissn><abstract>Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>37067406</pmid><doi>10.1128/cmr.00059-22</doi><tpages>33</tpages><orcidid>https://orcid.org/0000-0003-2370-2438</orcidid><orcidid>https://orcid.org/0000-0002-6284-2022</orcidid><orcidid>https://orcid.org/0000-0002-9969-3972</orcidid><orcidid>https://orcid.org/0000-0001-6590-6127</orcidid><orcidid>https://orcid.org/0000-0002-2296-2126</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-8512
ispartof Clinical microbiology reviews, 2023-06, Vol.36 (2), p.e0005922-e0005922
issn 0893-8512
1098-6618
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10283489
source American Society for Microbiology Journals; PubMed Central
subjects Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - therapeutic use
Bacteremia - drug therapy
Clinical Microbiology
Gram-Positive Bacterial Infections - drug therapy
Humans
Linezolid - therapeutic use
Review
Sepsis
Vancomycin - pharmacology
Vancomycin - therapeutic use
Vancomycin-Resistant Enterococci
title Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-13T07%3A46%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutics%20for%20Vancomycin-Resistant%20Enterococcal%20Bloodstream%20Infections&rft.jtitle=Clinical%20microbiology%20reviews&rft.au=Cairns,%20Kelly%20A&rft.date=2023-06-21&rft.volume=36&rft.issue=2&rft.spage=e0005922&rft.epage=e0005922&rft.pages=e0005922-e0005922&rft.issn=0893-8512&rft.eissn=1098-6618&rft_id=info:doi/10.1128/cmr.00059-22&rft_dat=%3Cproquest_pubme%3E2802423070%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a419t-d89c0d20fc49ab0518b1a61115a94678e7cb84afd13c3f433bf785c78a56b5c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2802423070&rft_id=info:pmid/37067406&rfr_iscdi=true